Do the Fertility Drugs Increase the Risk of Cancer? A Review Study

Zohre Momenimovahed1,2, Safoura Taheri3, Azita Tiznobaik4 and Hamid Salehiniya5,6*

1 Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Qom University of Medical Sciences, Qom, Iran, 2 Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran, 3 Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran, 4 Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Hamedan University of Medical Sciences, Hamedan, Iran, 5 Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran, 6 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Aim: All over the world, many couples cannot conceive a child and have problems with pregnancy. Ovulation-inducing drugs are among the most important drugs used for the treatment of infertility. In recent years, there have been many debates about the relationship between fertility medication and cancer. Due to the lack of comprehensive study of this matter, and as understanding the relationship between the use of fertility drugs and cancer is of importance, the present study was conducted to investigate the relationship between infertility drugs and cancer in women.

Materials and Methods: To determine the relationship between infertility treatment and cancer, a comprehensive search was carried out in databases such as; Medline, Web of Science Core Collection, and Scopus using keywords words; “infertility,” “ovulation induction,” “cancer,” “infertility treatment,” “ART,” “tumor,” “controlled ovarian stimulation,” “fertility agents,” and “neoplasms.” Full-text, English language, and original articles were included in this study.

Results: In total, 81 articles were entered into the study. The relationship between fertility medications and breast, ovary, endometrial, uterus, colon, thyroid, skin, cervical, and non-Hodgkin’s lymphoma cancers were studied. Although the relationship between fertility medications and cancer is theoretically justifiable, most studies have shown that risk of cancer will not increase after fertility treatment.

Conclusion: The results of this study did not show that fertility medications increase the risk of cancer among users. In summary, the relationship between infertility treatment and cancer incidence remains an open question.

Keywords: infertility, ovulation induction, cancer, infertility treatment, controlled ovarian stimulation, fertility agents, neoplasms

INTRODUCTION

All over the world, 48.5 million couples have problems with pregnancy, and many children are born with the help of fertility treatments, which primarily occurs in developing countries (1). After cancer and cardiovascular disease, infertility is the third most common disease (2). With increasing numbers of couples delaying parenting attempts, the prevalence of infertility is on the rise. Decreased fatality is one of the most important issues in Western countries, and is an essential
part of reproductive health (1), which affects different aspects of life and imposes huge economic burdens on societies (2). Infertility is affected by various physiological, genetic, environmental, social, infectious, and nutritional factors (1, 3). Assisted reproductive technology (ART) is one of the most important strategies used today to increase the chance of fertility among infertile people (4). The ART uses many medications and techniques to increase the chance of fertility (5). Ovulation-inducing drugs are among the most important drugs used for the treatment of infertility, which affect the ovaries by increasing the levels of estrogen, progesterone, and gonadotropins. Complications of these drugs include ovarian hyper-stimulation syndrome, osteoporosis, and adverse pregnancy outcomes (6, 7).

In recent years, there have been many debates about the relationship between ovulation-inducing drugs, infertility treatment, and cancer (8–10). Changes in endogenous hormones that occur following the use of these drugs have raised many concerns about the safety of these treatments. Due to increasing infertility and the subsequent increase in the use of fertility drugs in recent years, investigating the long-term effects of these drugs are considerably important. It also raises the following question: Can the use of fertility drugs in the long-term cause cancer? Since understanding the relationship between the use of fertility drugs and cancer is important and due to the lack of comprehensive study in this regard, the present study was conducted to investigate the relationship between infertility drugs and cancer among women.

MATERIALS AND METHODS

Search Strategy

To determine the relationship between infertility treatment and cancer, a comprehensive search for reliable articles was carried out in databases such as Medline, Web of Science Core Collection (Indexes = SCI-EXPANDED, SSCI, A & HCI Timespan), and Scopus (all years), using keywords, including “infertility,” “ovulation induction,” “cancer,” “infertility treatment,” “ART,” “tumor,” “controlled ovarian stimulation,” “fertility agents,” and “neoplasms.” Combinations of these keywords were also used for the search. All keywords were checked with PubMed Medical Subject Heading (MeSH). Then, a manual search was conducted in valid journals for full-text articles and related systematic reviews. All retrieved articles were entered into the Endnote X7 software in one database. In order to reduce errors during the review phase, the PRISMA statement and Moher et al. (11) guidance were used.

Inclusion Criteria

Two researchers carefully reviewed the retrieved articles. The criteria for entering the study included: full-text articles, English language and original articles (case-control, retrospective and prospective cohort), the use of keywords in the title or abstract, articles with an abstract, and articles that have reviewed a type of malignancies associated with the use of fertility drugs. In vitro fertilization (IVF) and each of the clomiphene citrate regimens, the gonadotropins, human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), gonadotropin-releasing hormone (GnRH) agonist, and antagonists were studied alone or in combination.

Exclusion Criteria

Case reports, case series, systematic reviews, meta-analysis, and animal studies were excluded.

Extracting and Analyzing the Data

The articles were categorized according to their specific characteristics including the number of participants, type of study, and type of fertility regimen. The risk scale in this study included; Standardized Incidence Ratio (SIR), Incidence Rate Ratio (IRR), Hazard Ratio (HR), and Odds Ratio (OR).

RESULTS

Characteristics of the Selected Studies

After a comprehensive search through the databases, 320 articles were entered into the study and the references of 41 articles were manually reviewed. Duplicate articles were removed using Endnote software (n = 160). During the initial evaluation, 201 articles were selected for the review. After reviewing the title and abstract, 95 articles that were not consistent with the purpose of this study or did not meet the inclusion criteria were removed. The full texts of other articles were carefully examined by two researchers, and 25 articles were removed for scientific reasons (literature review: 9, commentary: 6, not English language: 2, full text not available: 5, editorial: 3). At the end, 81 articles were selected for the review (Figure 1).

Relationship Between Steroid Hormones and Cancer

In general, cancer occurs as a result of the division of mutated cells. Therefore, the hormone and any factor that stimulates the growth of the cells can affect the occurrence of cancer (12). The relationship between steroid hormones and some types of cancers, such as breast and endometrium cancers, is well-documented (12–14). Estrogen, progesterone, and testosterone are steroid hormones that are produced following a series of biological responses and are derived from cholesterol. Estrogen, which is one of the most important female sex hormones, is produced in the ovaries, the adrenal cortex, and the placenta, and leads to the growth of the reproductive system and the development of sexual traits (15). Based on the results of studies, free estradiol and albumin-bound estradiol are associated with an increased risk of breast cancer (16) and can enhance the progression of metastatic breast cancer (17). High levels of estradiol and estrogen hormones in women with breast cancer contribute to the progression of metastatic breast cancer (18). Estrogen can contribute to the onset of cancer by affecting the mitosis duplication of epithelial cells. Increasing mitotic activity can play a role in increased probability of mutation and DNA damage, and reduced apoptosis and growth of early tumors (13, 19).

The role of gonadotropins in the occurrence of cancer has also been discussed by researchers. High levels of LH and FSH cause exposure to uncontested estrogen in the menstrual
cycle, which contributes to an increase in cancer. On the other hand, stimulating the synthesis of mitogenic growth factors by gonadotropins can contribute to the growth of breast cancer cells (20, 21). In addition, high levels of gonadotrophin, predict a weaker prognosis in people with breast cancer (21).

**Analysis Based on the Type of Cancer**

**Table 1**

**Breast Cancer**

Breast cancer is a multifactorial disease and several risk factors are involved in its onset. The majority of breast cancers are hormone dependent (22). Several studies have pointed to the etiologic role of endogenous and exogenous hormones in increasing the risk of breast cancer. Therefore, the possible relationship between ovulation-inducing drugs and increased risk of breast cancer has been the subject of discussions by researchers (23–25). Compared with normal ovulation cycle, oestradiol concentration increase up to 10-fold in ovulation stimulation cycle (26). Treatment with fertility drugs is associated with an increased risk of breast cancer diagnosis in the first year after the treatment (27). The result of a cohort study of 808,834 women showed that the risk of breast cancer increased in individuals who gave birth following ART [adjusted hazard risk (HR) 1.20, 95% CI 1.01–1.42]. However, in this study confounding factors such as age of menarche, family history, history of breastfeeding, and obesity were not controlled (28). In a cohort study, the risk of breast cancer was increased among individuals who used ovulation-inducing drugs, although this risk was not statistically significant in primiparous women (29). The result of a case-control study of 35–64 years old women showed that, although the use of fertility drugs was not associated with an increased risk of breast cancer in general, the relative risk of breast cancer in people who used hMG use for more than 6 months or 6 cycles was about 2.7–3.8 (30). A case-control study found that IVF treatment after the age of 30 years was associated with an increased risk of breast cancer, however, the characteristics of breast tumors in subjects treated with IVF did not differ with the general population (31). Although the results of the above studies suggest a relationship between infertility treatment and the risk of breast cancer, a large, population based cohort study between 1991 and 2010 stated, regardless of infertility treatment, the risk of breast cancer in people who are incapable of conceiving or maintaining fetuses is increased by 2 times (32). Meanwhile, many researchers could not show a positive relationship between fertility treatment and breast...
### TABLE 1 | Characteristic study of effects of fertility drugs on cancer.

| References | Country | Design | Period | Study population | Mean age at entry (Year) | Mean follow up (Year) | Adjusting factor(s) | Type of infertility treatment | Type of malignancy | Number of stimulated cycles | Effect estimates | Main finding(s) |
|------------|---------|--------|--------|------------------|--------------------------|------------------------|----------------------|-----------------------------|-----------------|--------------------------|----------------|----------------|
| Reigstad et al. (28) | Norway | Cohort | 1984–2010 | Total:808,834 | Case: 16,626 | Control: 792,208 | 16.0 (12,401,121 person-years) | Age | Parity | Age at first birth | Region of residence | IMF | ICSI | Breast | HR | Increased risk of breast cancer in women with ART. |
| Burkman et al. (30) | US | Case-Control | 1994–1998 | Case: 4,575 | Control: 4,682 | Age range: 35-64 | Age Race | Strata of study center | Ovarium citrate hMG | Breast | <6≥6 | OR | Increased risk of ductal breast cancer in women who use hMG. |
| Williams et al. (32) | UK | Cohort | 1991–2002 | Total:255,786 | 34.5 | 8.8 (2,257,789 person-years) | Age at cycle start | Parity | Infertility diagnosis | Number of ART cycles | Cumulative FSH dosage | ART outcome | Breast | Corpus uteri | Ovary | 1.8 | SIR | No association between ART and corpus uteri and invasive breast cancer risk. Increased risks of in situ breast cancer and invasive and borderline ovarian tumors in women with ART. |
| Dor et al. (23) | Israel | Cohort | 1981–1992 | Total:5,026 | 34.0 | 3.6 (18,291 person-years) | Age at cycle start | Parity | Infertility diagnosis | Number of ART cycles | Cumulative FSH dosage | ART outcome | Ovarium citrate hMG | GnRH analogs | Breast | Ovary | Cervix | Endometrium | 1≥6 | SIR | No association between fertility treatment and cancer risk. |
| Luke et al. (33) | US | Cohort | 2004–2009 | Total:113,226 | Case: 37.8 | Control:35.3 | 4.8 (263,457 person-years) | Age at cycle start | Parity | Infertility diagnosis | Number of ART cycles | Cumulative FSH dosage | ART outcome | Ovarium citrate hMG | FSHdominophene citrate | Breast | Endocrine | Melanoma | Breast | Ovary | Uterine | Female genital | 1, 2, 3, 4, or ≥5 | SIR | No association between fertility treatment and cancer risk. |
| Gauthier et al. (39) | France | Cohort | 1990–2000 | Total:92,555 | Case: 6,602 | Control: | Age range: 40-65 | Education | Smoking | BMI | Self and familial history of breast cancer | Age at menarche | Menopausal status | Parity | Age at first full term pregnancy | Ovarium citrate | Gonadotropins | Breast | Mean: 13 months | RR | No association between fertility treatment and breast cancer risk. |

(Continued)
| References       | Country | Design | Period       | Study population | Mean age at entry (Year) | Mean follow up (Year) | Adjusting factor(s) | Type of infertility treatment | Type of malignancy | Number of stimulated cycles | Effect estimates | Main finding(s)                                                                 |
|------------------|---------|--------|--------------|------------------|--------------------------|------------------------|---------------------|--------------------------|-----------------|-----------------------------|------------------|-------------------------------------------------------------------------------|
| Jensen et al. (40) Denmark Cohort 1965–1998 | Total:54,379 | 8.8 | Number of childbirth | FSH hCG hMG GnRH | Breast | RR | No association between fertility treatment and breast cancer risk. |
| Sanner et al. (47) Sweden Cohort 1961–2004 | Total:2,768 | Age range: 16–45 | Indication of treatment Age OCP Parity Pelvic surgery before the infertility treatment Pregnancy with completed birth in the follow-up period | Ovarian citrate Gonadotropins | Ovary | 1–4 cycles | SIR | RR | No association between hormonal infertility treatment and invasive ovarian epithelial cancer. |
| Silva et al. (48) London Cohort 1963–1999 | Case:7,425 Control: 1,727 | 28.1 | Age Parity | Ovarian citrate Gonadotropins | Ovary | 2–3 cycles | Period-age-standardized mortality (SMR) | SIR | No association between ovulation stimulation drugs and cancer risk. |
| Potashnik et al. (49) Israel Cohort 1960–1984 | Total:1,197 | 27.5 | Age Parity | Ovarian citrate hMG | Breast | SIR | No association between fertility drugs and cancer risk. |
| Venn et al. (50) Australia Cohort 1978–1992 | Total:10,358 | Case: 5,564 Control: 4,794 | Case: 5.2 | Age Infertility type | Ovarian citrate | Breast | Median: 2 cycles | SIR | No association between IVF and cancer risk. |
| Franceschi et al. (51) Italy Case-Control 1992 | Case: 195 Control: 1,339 | 28.7 | Study site Age Gravity | Ovarian citrate hMG | Ovary | SIR | No association between ovulation stimulation drugs and ovarian cancer risk. |
| Modan et al. (55) Israel Cohort 1964–1974 | Total:2,496 | 21.4 | (54,413 person-years) | Ovarian citrate hMG | Ovary | SIR | No association between ovulation stimulation drugs and cancer risk. (exception: Use of Ovarian citrate and failure to pregnancy was related to ovarian cancer risk) |
| Trabert et al. (53) US Cohort 1965–1988 | Total:9,825 | 17.6 | (256,448 person-years) | Ovarian citrate | Ovary | ≥6 | RR | No association between ovulation stimulation drugs and ovarian cancer risk. |

(Continued)
| References | Country | Design | Period | Study population | Mean age at entry (Year) | Mean follow up (Year) | Adjusting factor(s) | Type of infertility treatment | Type of malignancy | Number of stimulated cycles | Effect estimates | Main finding(s) |
|------------|---------|--------|--------|------------------|-------------------------|----------------------|---------------------|-----------------------------|------------------|--------------------------|----------------|----------------|
| Jensen et al. (54) Denmark | Cohort | 1963–1998 | Total: 54,362 | 30 | 16.0 | Parity | Ovum | Ovary | 1-10 | RR | No association between fertility drugs and cancer risk. |
| Doyle (96) UK | Cohort | 1975–1989 | Total: 5,556 | 43,811 | Age, Calendar year, Parity following the last treatment cycle | Ovum | Ovary | SIR | No association between fertility drugs and cancer risk. |
| Stewart et al. (87) Australia | Cohort | 1982–2002 | Total: 21,639 | 31.2 | 16.5 | Age, Socioeconomic status | Ovum | Ovary | HR | Increased risk of borderline ovarian tumors in women with IVF. |
| Mosgaard et al. (58) Denmark | Case-Control | 1989–1994 | Case: 231 Control: 1,721 | 43.6 | 33.8 | Age, Region of residence, Use of oral contraceptives, Use of hormone replacement therapy, Smoking | Ovum | Ovary | OR | No association between fertility drugs and borderline ovarian cancer risk. |
| Bjørnholt et al. (59) Denmark | Cohort | 1963–2006 | Total: 96,545 | 30.3 | 11.3 | Parity, Cause of infertility | Ovum | Ovary | 1-4 | RR | No association between fertility drugs and borderline ovarian cancer risk. |
| Liat et al. (24) Israel | Cohort | 1964–1974 | Total: 2,431 | 28.6 | 33.8 | Ovum, Breast, Endometrium | Ovum | Ovary | SIR | No association between fertility drugs and borderline ovarian cancer risk. |
| Althuis et al. (69) US | Cohort | 1965–1988 | Total: 8,431 | 30 | 18.8 | Age, Calendar year, Study site, Parity | Ovum | Uterine | <6-6 | RR | Increased risk of uterine cancer in women who use domiphen citrate. |
| Jensen et al. (70) Denmark | Cohort | 1965–1998 | Total: 54,362 | 30 | 16.0 | Parity | Ovum | Uterine | 1-10 | RR | Increased risk of uterine cancer in women who use gonadotropins, clomiphen and human chorionic gonadotropin. |
| References | Country | Design | Period | Study population | Mean age at entry (Year) | Mean follow up (Year) | Adjusting factor(s) | Type of infertility treatment | Type of malignancy | Number of stimulated cycles | Effect estimates | Main finding(s) |
|------------|---------|--------|--------|------------------|--------------------------|------------------------|---------------------|-----------------------------|-----------------|--------------------------|----------------|----------------|
| Hannibal et al. | Denmark | Cohort | 1963–1998 | Total: 54,362 | 30 | 8.8 | Age at first live birth | Ovulation induction | Thyroid | 1–6 | RR | Increased risk of thyroid cancer in women who use clomiphene |
| Calderon-Margalit. | Israel | Cohort | 1974–2004 | Total: 14,463 | 28.1 | 29.0 (424,193 person-years) | Age, Socioeconomic status, Mother’s geographic origin, Body mass index, Parity | Ovulation induction | Breast, Uterus, Ovary, Cervix, Non-Hodgkin lymphoma, Malignant melanoma, Thyroid, Colon | HR | No association between fertility drugs and ovarian cancer risk. Increased risk of uterine and borderline breast cancer, malignant melanoma and non-Hodgkin lymphoma in women who use ovulation induction |
| Kallen et al. | Sweden | Case-Control | 1982–2006 | Case: 24,058 | 32.0 | Year of delivery, Maternal age, Parity, Smoking | IVF | Breast, Cervix, Ovary, Placenta, CNS, Malignant melanoma, Thyroid, Colon | OR | Decreased risk of breast and cervical cancer in women with IVF |
| Leeuwen et al. | Netherlands | Cohort | 1983–2007 | Case: 19,146 | 14.7 | Age, Parity, Subfertility cause | IVF | Ovary | 1–5 | SIR | Increased risk of borderline ovarian cancer in women with IVF |
| Orgeas et al. | Sweden | Cohort | 1961–2004 | Total: 1,135 | 27 | 35,092 person-years | Age, Calendar period of breast cancer diagnosis, Age at first birth, Parity | Ovulation induction | Breast | 1–4 | SIR | No association between fertility drugs and breast cancer risk. |
| Lundborg et al. | Sweden | Cohort | 1982–2012 | Total: 1,340,211 | Case: 9.6 | Age, Parity, Calendar time, Educational level, Country of birth, Family history of breast cancer, Age at first birth | Ovulation induction | Breast | HR | No association between ovarian stimulation and breast cancer risk. |
Ovarian Cancer

Ovarian cancer is a rare and the most fatal gynecological disease worldwide (41). Regardless of infertility treatments, the risk of ovarian cancer may be altered with nulliparity (24), and infertility (42, 43). Therefore, the relationship between infertility treatment and ovarian cancer is difficult to prove. The “incessant ovulation theory” states that uninterrupted ovulation can contribute to the development of ovarian cancer by damaging ovary epithelium and, therefore, any factor that contributes to the reduction of ovulation can have a protective effect against ovarian cancer (44).

Many studies have indicated that an increased risk of ovarian cancer is associated with the intake of clomiphene citrate and gonadotropin (25, 45). A cohort study conducted from 1988 to 2013 revealed that, the risk of ovarian cancer is increased in individuals treated with IVF (adjusted HR 3.9; 95% CI 1.2–12.6), (46). The results of a cohort study showed an increase in the incident of ovarian cancer after exposure to clomiphene citrate. The results also indicated that risk of cancer increases with increasing dosage of the drug among nulliparous women (25).

Use of clomiphene citrate, due to ovulation disorders, increases the risk of ovarian cancer (SIR = 7.47; 95% CI 1.54–21.83), (47). Although a number of studies have suggested that using ovulation-inducing drugs is associated with ovarian cancer, many of them have not shown any significant increase in the risk of ovarian cancer by taking ovulation-inducing drugs (29, 33, 48–52). The result of a retrospective cohort study showed that women who use clomiphene citrate and remained nulligravid are more likely to develop ovarian cancer than those who use this drug and get pregnant (RR 3.63, 95% CI 1.36–9.72 vs. RR 0.88, 95% CI 0.47–1.63), (53). In a cohort study of 54,362 women, authors reported that the risk of ovarian cancer does not increase with the use of clomiphene citrate, gonadotropins, human chorionic gonadotropin, and gonadotropin-releasing hormone, and that there is no relationship between the duration of drug use, duration of follow-up, and pregnancy (54). An increased risk of ovarian cancer among those taking ovulation-inducing drugs should be an issue of interest to therapists and, therefore, more attention should be paid to the people’s choices (45).

In several studies, researchers have investigated the relationship between borderline ovarian tumors and fertility treatments. The risk to develop borderline ovarian tumors
increased in women undergoing IVF, while childbirth, hysterectomy and sterilization do not have protective effects (55). In a cohort study, the use of clomiphene citrate and gonadotropins increased the risk of borderline ovarian tumors by up to 3 times (SIR = 3.61; 95% CI 1.45–7.44), (47). A case-control study showed a relationship between borderline ovarian tumors and the use of ovulation-inducing drugs, especially hMG (56). The result of a study revealed that, although treatment with clomiphene citrate for <1 year is not associated with an increase in the risk of borderline tumors, its prolonged use increases this risk (57). In a case-control study, researchers concluded that, regardless of treatment, the risk of borderline ovarian tumors is two times higher in nulliparous women (58). Other researchers, however, could not show such a relationship (59, 60). A case-control study examined the correlation between five groups of fertility drugs including clomiphene citrate, human menopausal gonadotropins and follicle stimulating hormone, gonadotropin-releasing hormone analogs, human chorionic gonadotropins, progesterone and borderline ovarian tumors. The study found that use of progesterone was associated with an increased in borderline ovarian tumors, especially serous tumors, but no correlation was found between the borderline ovarian tumors and the use of other drugs (59). There is an ongoing debate about the relationship between fertility treatments and the risk of ovarian cancer and, so far, there has been no definitive evidence to confirm such relationship (24, 61, 62). The relationship between these drugs and the borderline ovarian tumors has only been reported in some studies (56, 63, 64).

Endometrial and Uterine Cancer

Endometrial cancer is one of the hormone-related cancers. Although the relationship between endometrial cancer and ovulation-inducing drugs is not clear, it appears that these drugs increase mitosis activity, DNA replication, mutation and malignancy by increasing serum level of estradiol during the follicular phase (65). However, by increasing oocyte cycles and pregnancy, the level of progesterone is significantly increased, and this plays a protective role against endometrial cancer. Results of several cohort studies showed an increase in endometrial cancer among women who used clomiphene citrate (24, 25). In a cohort study, researchers reported the highest increase in endometrial cancer among nulliparous women and those who have used more than 6 cycles of clomiphene (25). A cohort study which lasted for 30-years revealed that infertility is associated with an increased risk of endometrial cancer, and this risk does increase by ovulation induction (24). This is consistent with the finding of Brinton’s study (66). The results of a case-control study supported previous research and stated duration of use of fertility drugs was positively associated with endometrial cancer risk (OR = 6.10; 95% CI, 0.96–38.6) (67). There have been a few studies that did not show any relationship between fertility treatment and endometrial cancer (68).

According to a cohort of 29,700 IVF women, the incidence of uterine sarcoma increases in women who have history of infertility (8). In a large cohort study, authors reported that the risk of uterine cancer in people taking ovulation-stimulating drugs is increased by 3 times, and this risk will increase by 8 times after taking clomiphene citrate for 12 months (29). Based on the results of a retrospective cohort study, the risk of uterine cancer increases with the increase in the dose of clomiphene citrate, its cycle of use, and the time since its first use, The risk is also increased in nulligravid and obese individuals (69). A cohort study concluded that consumption of more than 2,250 mg of clomiphene is associated with a 2.6-fold increase in the risk of uterus cancers (48). In 2009, researchers in a population based cohort study pointed to the relationship between the high dosages of gonadotropins and hCG and uterine cancer among the gonadotropins and hCG users (70). Infertility drugs may increase estrogen level during the follicular phase of ovulation stimulation cycles, and use of hCG and clomiphene for more than 6 months may increase the risk of uterine cancer (54). In general, uterine and endometrial cancers do not have high prevalence among different age groups, especially young people who are the target group in most studies, and therefore it is challenging to determine the relationship between endometrial cancer and the use of ovulation-inducing drugs.

Thyroid Cancer

The effect of exogenous hormonal agents on estrogen dependent malignancies has been discussed by many researchers. Stimulation of ovulation is associated with increased level of TSH hormone in the circulation, which causes cell proliferation in the gland (25). Some medications, such as clomiphene citrate, may have a greater effect on the thyroid gland due to longer half-life (71). The results of various studies suggest a link between thyroid cancer and ART (25, 71). A cohort study concluded that, the use of clomiphene citrate is associated with a 2-fold increase in the risk of thyroid cancer, and this risk is not statistically significant among the users of gonadotropins, hCG, and GnRH (71). The risk of thyroid cancer is higher among nulligravid women who take clomiphene citrate (72, 73). However, in a cohort study, the risk of thyroid cancer was higher among parous individuals who were taking clomiphene citrate (71). The use of clomiphene (RR = 2.28; 95% CI: 1.08–4.82) and progesterone (RR = 10.14; 95% CI: 1.93–53.33) is associated with an increased risk of thyroid cancer (71). Other studies have not shown any relationship between fertility drugs and thyroid cancer. Authors in a cohort study stated that there is no evidence of any relationship between gonadotropins and thyroid cancer (73). In a study, aggressive pattern of papillary thyroid carcinoma was seen among thyroid cancer patients who had received IVF treatment in the past and this may cause a delay in the thyroid cancer diagnosis. In this study, thyroid cancer was diagnosed after 4 years from the last IVF treatment (74). The present study did not find any relationship between fertility treatment and thyroid cancer.

Skin Cancer

Skin cancer endangers many people's lives due to death or disability. Age, gender, diet, and genetics affect incidence of this cancer (75). Potential effect of oral contraceptive pills on melanoma (76, 77), has been a source of concern for researchers about the role of fertility drugs on this cancer. In a cohort study, the incident of skin cancer (except melanoma) was higher in those who were using IVF treatment (78). Researchers stated that,
although in general infertility treatment is not associated with the risk of malignant melanoma, the use of clomiphene citrate is associated with an increased risk of malignant melanoma, and this risk is more pronounced among those who have been waiting for pregnancy for more than a year (29). In a cohort study, authors concluded that although infertility is not associated with an increased risk of malignant melanoma, exposure to fertility drugs in women with infertile partners increases the risk of melanoma, and this risk is also reduced in women who receive a low dose of fertility drugs (79). According to a retrospective cohort study, infertile women with progesterone deficiencies had higher melanoma risk (80). In a retrospective cohort study among 8,422 women in 1965–1988, the researchers confirmed this result and concluded that, the use of fertility treatment does not significantly alter the risk of melanoma. In this study, clomiphene citrate had a stronger effect on the risk of melanoma (RR = 2; 95% CI: 0.9–4.6) (73). Overall, the results of studies have shown no relationship between the risk of melanoma and fertility drugs.

Colon Cancer
Although lifestyle is one of the most important risk factors for colon cancer, sex hormones may also affect the etiology of colon cancer. The results of a cohort study showed that infertility treatment does not increase the risk of colon cancer (73). The result of a 21-year follow-up in a cohort study showed that ovarian stimulation for IVF does not increase the risk of breast cancer in comparison with the general population (81). Furthermore, after a 30 year follow-up of 9,892 women treated with pre-IVF fertility drugs, researchers found that these drugs have no effect on colorectal cancer. The increase in IVF cycles and a greater amount of gonadotropin ampoules did not alter this risk (72). Other studies showed that ovulation stimulation for IVF does not increase the risk of colon cancer in comparison with the general population (48, 81). Estrogen is considered to be protective against colorectal cancer (82), and so this cancer is expected to decrease in women who use fertility drugs. In addition, lower level of insulin-like growth factor I in women who use exogenous hormones, may play a role in reducing colorectal cancer in these group (81). Generally, the results of present study suggest that fertility treatment is not a risk factor for colon cancer.

Cervical Cancer
Cervical cancer is the fourth most common cancer among women (83). Twenty years follow up of 8,422 women during 1965–1988 showed that infertility treatment does not change the risk of cervical cancer (73). According to a cohort study, ovulation induction reduces the risk of cervical cancer (48). Other cohort studies reported a lower risk of cervical cancer in people undergoing IVF treatment (23, 78, 84). Ultimately, researchers have reported that, due to regular screening and periodic examinations of infertile people, the risk of cervical cancer is lower among these people (25). In addition, parity and full-term pregnancy increase the risk of cervical cancer, therefore, it seems that this cancer is less prevalent among infertile women (83).

Non-Hodgkin’s Lymphoma
Ovulation induction is associated with an increased risk of non-Hodgkin’s lymphoma, and this risk is more pronounced in primiparous women as well as the first 5 years after childbirth (HR 2.63, 95% CI: 1.02, 6.82) (29).

CONCLUSION
The purpose of this study was to determine the relationship between the use of fertility drugs and cancer. Due to the correlation between hormonal and reproductive factors and women’s cancers, much more attention has been paid to the relationship between the use of fertility drugs and cancer in recent years. Although this relationship is theoretically justifiable, the complex and multiple factors that are involved in the onset of cancer make it difficult to determine the definite relationship between the use of these drugs and cancer. In spite of the relationship that exists between the ovulation-inducing drugs and cancer in some cohort studies, the results of our study showed no significant increase in the incidence of cancer by infertility treatment. According to the results of this study, there is no definitive relationship between the use of fertility drugs and cancer, and only some observational studies have pointed to this relationship. So, the following question still cannot be answered: Are fertility drugs safe?

Although, the small sample size, short-term follow-up, and lack of control over confounding variables are some of the most important limitations of such studies, more studies are needed to achieve a better result. Since, the large proportion of people who use ovulation-inducing drugs are young, long-term follow-up can better detect the onset of cancer among them. At the end, the relationship between infertility treatment and cancer incidence remains an open question.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES
1. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. (2012) 9:e1001356. doi: 10.1371/journal.pmed.1001356

2. Cong J, Li P, Zheng L, Tan J. Prevalence and risk factors of infertility at a rural site of Northern China. PLoS One. (2016) 11:e0155563. doi: 10.1371/journal.pone.0155563

3. Brugo-Olmedo S, Chilik K, Kopelman S. Definition and causes of infertility. Reprod Biomed Online. (2001) 2:173–85. doi: 10.1016/S1472-6483(10)62193-1
Perspective of 30 years of follow-up. *Gynecol Endocrinol.* (2012) 28:809–14. doi: 10.3109/09513390.2012.671391

25. Reigstad MM, Storen R, Myklebust TA, Olderdie NB, Omland AK, Robsahm TE, et al. Cancer risk in women treated with fertility drugs according to status—a registry-based cohort study. *Cancer Epidemiol Prevent Biomark.* (2017) 26:953–62. doi: 10.1158/1055-9965.EPI-16-0809

26. Sonmez M, Oktay K. Fertility preservation in female patients. *Hum Reprod Update.* (2004) 10:251–66. doi: 10.1093/humupd/dmh021

27. Venn A, Watson L, Brunsma S, Giles G, Healy D. Risk of cancer after use of fertility drugs with *in-vitro* fertilization. *Lancet.* (1999) 354:1586–90. doi: 10.1016/S0140-6736(99)05203-4

28. Reigstad MM, Larsen IK, Myklebust TÅ, Robsahm TE, Olderdie NB, Omland AK, et al. Risk of breast cancer following fertility treatment—a registry based cohort study of parous women in Norway. *Int J Cancer.* (2015) 136:1140–8. doi: 10.1002/ijc.29069

29. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin M, Manor O, et al. Cancer risk after exposure to treatments for ovulation induction. *Am J Epidemiol.* (2008) 169:365–75. doi: 10.1093/aje/kwn318

30. Burkmann RT, Tang M-TC, Malone KE, Marchbanks PA, McDonald JA, Folger SG. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child health and human development women's contraceptive and reproductive experiences study. *Fertil Steril.* (2003) 79:844–51. doi: 10.1016/S0015-0282(02)04950-6

31. Katz D, Paliel O, Perez T, Revel A, Sharon N, Maly B, et al. Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control study. *Breast J.* (2008) 14:517–22. doi: 10.1111/j.1524-741X.2008.00614.x

32. Williams CL, Jones ME, Swerdlov AJ, Botting BJ, Davies MC, Jacobs I, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. *BMJ.* (2018) 362:k2644. doi: 10.1136/bmj.k2644

33. Luke B, Brown MB, Spector LG, Missamer SA, Leach RE, Williams M, et al. Cancer in women after assisted reproductive technology. *Fertil Steril.* (2015) 104:1218–26. doi: 10.1016/j.fertnstert.2015.07.1135

34. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. *Arch Intern Med.* (2006) 166:2484–9. doi: 10.1001/archinte.166.22.2484

35. Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadarian P, et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. *Cancer Causes Control.* (2008) 19:1111–9. doi: 10.1007/s10552-008-9175-0

36. Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. *Hum Reprod.* (1999) 14:1653–5. doi: 10.1093/humrep/14.6.1653

37. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S. Fertility treatment and risk of breast cancer. *Hum Reprod.* (1996) 11:300–3. doi: 10.1093/HUMREP/11.2.300

38. Bernstein L, Hanisch R, Sullivan-Halley J, Ross RK. Treatment with human chorionic gonadotropin and risk of breast cancer. *Cancer Epidemiol Biomark Prev.* (1995) 4:347–40.

39. Gauthier E, Pauletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. *Hum Reprod.* (2004) 19:2216–21. doi: 10.1093/humrep/deh422

40. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. *Cancer Epidemiol Biomark Prev.* (2007) 16:1400–7. doi: 10.1158/1055-9965.EPI-07-0075

41. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. 2012. *CA Cancer J Clin.* (2013) 65:87–108. doi: 10.3322/caac.21262

42. Rasmussen ELK, Hannibal CG, Dehlendorff C, Baandrup L, Junge J, Vang R, et al. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study. *Gynecol Oncol.* (2017) 144:571–6. doi: 10.1016/j.ygyno.2017.01.002

43. Rodriguez C, Tahmam LM, Calle EE, Thun MJ, Jacobs EL, Heath CW Jr. Infertility and risk of fatal ovarian cancer in a
The possible association between in vitro fertilization treatments and cancer development. *Int J Gynecol Cancer*. (2003) 13:23–7. doi: 10.1111/j.1525-1660.2003.00004.x

van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for *in vitro* fertilization in a large Dutch cohort. *Hum Reprod.* (2011) 26:3456–65. doi: 10.1093/humrep/der322

Ness RB, Cramer DW, Goodman MT, Kjer SK, Malin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. *Am J Epidemiol.* (2002) 155:217–24. doi: 10.1093/aje/kwj317

Louis LS, Saso S, Ghaem-Maghami S, Abdalla H, Smith JR. The relationship between infertility treatment and cancer including gynaecological cancers. *Obstet Gynaecol (2013) 115:77–83. doi: 10.1111/jog.12040

Brinton LA, Westhoff CL, Soccia B, Lamb EL, Althuis MD, Mabie JE, et al. Causes of infertility as predictors of subsequent cancer risk. *Epidemiology.* (2005) 16:500–7. doi: 10.1097/01.ede.0000164812.02181.d5

Parazzini F, Pelucchi C, Talani M, Montella M, La Vecchia C. Use of fertility drugs and risk of uterine cancer: results from a large Danish population-based cohort study. *Br J Cancer.* (2009) 100:1824. doi: 10.1038/sj.bjc.6605086

Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E. Effects of ovulation induction and drug risk of endometrial cancer: a pilot study. *Eur J Obstet Gynaecol Reprod Biol.* (2001) 98:53–7. doi: 10.1016/S0301-2115(01)00344-X

Althuis MD, Moghissi KS, Westhoff CL, Soccia B, Lamb EL, Lubin JH, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. *Am J Epidemiol.* (2005) 161:607–15. doi: 10.1093/aje/kwi084

Jensen A, Sharif H, Kjer SK. Use of fertility drugs and risk of uterine cancer: results from a large Danish population-based cohort study. *Am J Epidemiol.* (2009) 170:1408–14. doi: 10.1093/aje/kwp290

Hannibal CG, Jensen A, Sharif H, Kjer SK. Risk of thyroid cancer after exposure to fertility drugs: results from a large Danish cohort study. *Hum Reprod.* (2007) 23:451–6. doi: 10.1093/humrep/dem381

Brinton LA, Moghissi KS, Soccia B, Lamb EL, Trabert B, Niwa S, et al. Effects of fertility drugs on cancers other than breast and gynecologic malignancies. *Fertil Steril.* (2015) 104:880–8. doi: 10.1016/j.fertnstert.2015.06.045

Althuis MD, Soccia B, Lamb EL, Moghissi KS, Westhoff CL, Mabie JE, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. *Am J Obstet Gynecol.* (2005) 193:668–74. doi: 10.1016/j.amjog.2005.01.091

Pazaitou-Panayiotou K, Toulis K, Mandanas S, Tarlatzis B. Thyroid cancer after *in vitro* fertilization: a retrospective, non-consecutive case-series analysis. *Gynecol Endocrinol.* (2014) 30:569–72. doi: 10.1093/gynen/9901553049.2014.97258

Pakrad, R, Ghonech, M, Pournavard M, Pakrad J, Momenimovahed Z, Salehiniya H, et al. Spatial analysis of skin cancer incidence in Iran. *Asian Pacific J Cancer Prevent.* (2016) 17:33–7. doi: 10.7314/APJCP.2016.17.53.33

Feskanchik D, Hunter D, Willlett W, Spiegelman D, Stampfer M, Speizer F, et al. Oral contraceptive use and risk of melanoma in premenopausal women. *Br J Cancer.* (1999) 81:918. doi: 10.1038/sj.bjc.6607987

Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. *Br J Cancer.* (1984) 50:681. doi: 10.1038/bjc.1984.236

Yi-Kuha A-N, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. *Hum Reprod.* (2012) 27:1146–55. doi: 10.1093/humrep/des103

Young P, Purdie D, Jackman L, Molloy D, Green A. A study of infertility treatment and melanoma. *Melanoma Res.* (2001) 11:535–41. doi: 10.1097/00008389-200110000-00015

Brinton LA, Melton LJ III, Malkasian GD Jr., Bond A, Hoover R. Cancer risk after evaluation for infertility. *Am J Epidemiol.* (1989) 129:712–22. doi: 10.1093/oxfordjournals.aje.a115186

Spaan M, Van Den Belt-dusebout AW, Burger CW, van Leeuwen FE, Schats M, Lambalk C, et al. Risk of colorectal cancer after ovarian stimulation for *in vitro fertilization*. *Clin Gastroenterol Hepatol.* (2016) 14:279–37. e5. doi: 10.1016/j.cgh.2015.12.018

Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. *Cancer Causes Control.* (2007) 18:723–33. doi: 10.1007/s10555-007-9105-7

Momenimovahed Z, Salehiniya H. Incidence, mortality and risk factors of cervical cancer in the world. *Biomed Res Ther.* (2017) 4:1795–81. doi: 10.15419/bmrat.v4i12.386

Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olaussen PO. Malignancies among women who gave birth after *in vitro fertilization*. *Hum Reprod.* (2011) 26:253–8. doi: 10.1093/humrep/deq307

Modan B, Ron E, Lerner-Geva L, Blumberg T, Menczer J, Rabinovich J, et al. Cancer incidence in a cohort of infertile women. *Am J Epidemiol.* (1998) 147:1038–42. doi: 10.1093/oxfordjournals.aje.a009397
86. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. *Hum Reprod*. (2002) 17:2209–13. doi: 10.1093/humrep/17.8.2209
87. Stewart LM, Holman CAJ, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. *Gynecol Oncol*. (2013) 128:260–4. doi: 10.1016/j.ygyno.2012.10.023
88. Moleti M, Sturniolo G, Di Mauro M, Russo M, Vermiglio F. Female reproductive factors and differentiated thyroid cancer. *Front Endocrinol*. (2017) 8:111. doi: 10.3389/fendo.2017.00111
89. Orgeas CC, Sanner K, Hall P, Conner P, Holte J, Nilsson SJ, et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. *Am J Obstet Gynecol*. (2009) 200:72.e1–7. doi: 10.1016/j.ajog.2008.08.066
90. Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Bergh C, Gemzell-Danielsson K, Johansson AL. Ovarian stimulation and risk of breast cancer in Swedish women. *Fertil Steril*. (2017) 108:137–44. doi: 10.1016/j.fertnstert.2017.05.010
91. Kristiansson P, Björ O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. *Hum Reprod*. (2007) 22:421–6. doi: 10.1093/humrep/dei411
92. Puppo I, Lerner-Geva L, Halevy A, Olmer L, Friedler S, Raziel A, et al. The possible association between IVF and breast cancer incidence. *Ann Surg Oncol*. (2008) 15:1048–55. doi: 10.1245/s10434-007-9800-2

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Momenimovahed, Taheri, Tiznobaik and Salehinia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*